PL EN


Preferences help
enabled [disable] Abstract
Number of results
2012 | 8 | 4 | 351-359
Article title

Leki przeciwhistaminowe 2 generacji w praktyce codziennej

Authors
Content
Title variants
EN
Second generation antihistamines in everyday practice
Languages of publication
EN PL
Abstracts
EN
Second generation antihistamines have been commonly used in treatment of allergic disorders for decades, especially in allergic rhinitis, urticaria, atopic dermatitis and allergic conjunctivitis. They are frequently used in everyday clinical practice, mainly because of high efficacy and excellent safety profile. In allergic disorders we use the potency of antihistamines to bind to histamine receptors, while in other diseases we use them because of their possible anti‑inflammatory mechanisms. Antihistamines are usually administered in monotherapy, however, in some cases we combine them with other agents. Certain antihistamines drugs have similar mechanisms of action, however, we can find distinct differences between the drugs. This is the reason why in case of no significant clinical improvement it is possible to add one antihistamine drug to another in order to enhance efficacy, it is also possible to increase a single therapeutic dose even up to four times. These observations based on clinical experience are the reason why it is necessary to conduct further studies on schemes of antihistamines drugs’ administration. In the article frequently used drugs are presented, especially their clinical efficacy and safety. Results of chosen clinical trials are also reported. Some controversial topics are mentioned, especially combined use of certain drugs and the possibility of applying higher daily doses.
PL
Leki przeciwhistaminowe II generacji stosowane są od wielu lat w leczeniu chorób alergicznych, szczególnie alergicznego nieżytu nosa, pokrzywki, atopowego zapalenia skóry i alergicznego zapalenia spojówek. Należą do najczęściej przepisywanych leków w codziennej praktyce lekarskiej, głównie ze względu na wysoką skuteczność terapeutyczną i dobry profil bezpieczeństwa. W chorobach alergicznych istotny jest ich efekt wiązania z receptorami histaminowymi, natomiast w innych jednostkach opieramy się na własnym doświadczeniu i wykorzystujemy ich potencjalne działanie przeciwzapalne. Leki przeciwhistaminowe często stosowane są w monoterapii, niekiedy w skojarzeniu z innymi lekami. Poszczególne leki, mimo że mechanizm ich działania jest podobny, nieznacznie różnią się od siebie. Z tego względu przy braku efektu klinicznego zawsze warto zamienić lek antyhistaminowy na inny lub dołączyć inny preparat w dowolnym schemacie. Można również manipulować dawkami, podwyższając je nawet czterokrotnie w stosunku do dawek zarejestrowanych. Chociaż leki przeciwhistaminowe stosuje się od wielu lat, konieczne są zatem dalsze badania, mające na celu optymalizację schematów postępowania, ze szczególnym uwzględnieniem łączenia poszczególnych preparatów i stosowania zróżnicowanych dawek. W artykule omówiono najczęściej stosowane leki przeciwhistaminowe, ich skuteczność terapeutyczną i bezpieczeństwo ich stosowania. Przedstawiono wyniki wybranych badań klinicznych oraz poruszono zagadnienia kontrowersyjne, takie jak łączenie oraz stosowanie poszczególnych preparatów w wyższych dawkach dziennych.
Discipline
Year
Volume
8
Issue
4
Pages
351-359
Physical description
References
  • 1. Brunton S.A.: Allergy management strategies: An update. Patient Care 2002 Spring; 46 (supl.): 16-25.
  • 2. Kaplan A.: Chronic urticaria: pathogenesis and treatment. J. Allergy Clin. Immunol. 2004; 114: 465-474.
  • 3. Kaplan A.P.: Clinical practice. Chronic urticaria and angioedema. N. Engl. J. Med. 2002; 346: 175-179.
  • 4. Zuberbier T, Mtazberger C., Haustein U. i wsp.: Doubleblind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology (Basel, Switzerland) 1996; 193: 324-327.
  • 5. Zuberbier T., Asero R., Bindslev-Jensen C. i wsp.: EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427-1443.
  • 6. Staevska M., Popov T, Kralimarkova T. i wsp.: The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J. Allergy Clin. Immunol. 2010; 125: 676-682.
  • 7. Siebenhaar F., Degener F., Zuberbier T. i wsp.: High-dose desloratadine decreases wheat volume and improves cold provocation thresholds as compared with standard dose treatment in patients with acqiured cold urticaria: a randomized, placebo-controlled, crossover study. J. Allergy Clin. Immunol. 2009; 123: 672-679.
  • 8. Asero R.: Chronic unremitting urticaria: is the use of antihistamines above the licensed dose efective? A preliminary study of cetirizine at licensed and abovelicensed doses. Clin. Exp. Dermatol. 2007; 32: 34-38.
  • 9. Corcóstegui R., Labeaga L., Innerarity A. i wsp.: Preclin-ical pharmacology of bilastine, a new selective histamine Hj receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R.D. 2005; 6: 371-384.
  • 10. Corcóstegui R., Labeaga L., Innerarity A. i wsp.: In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs R.D. 2006; 7: 219-231.
  • 11. Sologuren A., Valiente R., Crean C. i wsp.: Relationship of dose to inhibition of wheal and flare for 5 doses of bilastine and 10 mg cetirizine (abstract). J. Clin. Pharmacol. 2007; 47: 1198.
  • 12. Simons F.E., McMillan J.L., Simons K.J.: A doubleblind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole, and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheals and flares during 24 hours in normal subjects. J. Allergy Clin. Immunol. 1990; 86: 540-547.
  • 13. Spicak V, Dab I., Hulhoven R. i wsp.: Pharmacokinetics and pharmacodynamics of cetirizine in infants and toddlers. Clin. Pharmacol. Ther. 1997; 61: 325-330.
  • 14. Berkowitz R.B., Dockhorn R., Lockey R i wsp.: Comparison of efficacy, safety, and skin test inhibition of cetirizine and astemizole. Ann. Allergy Asthma Immunol. 1996; 76: 363-368.
  • 15. Weller K., Maurer M.: Desloratadine inhibits human skin mast cell activation and histamine release. J. Invest. Dermatol. 2009; 129: 2723-2726.
  • 16. Frossard N., Strolin-Benedetti M., Purohit A. i wsp.: Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br. J. Clin. Pharmacol. 2008; 65: 172-179.
  • 17. Lippert U., Moller A., Welker P. i wsp.: Inhibition of cytokine secretion from human leukemic mast cells and basophils by Hr and H2-receptor antagonists. Exp. Dermatol. 2000; 9: 118-124.
  • 18. Hamman M.A., Bruce M.A., Haehner-Daniels B.D., Hall S.D.: The effect of rifampin administration on the disposition of fexofenadine. Clin. Pharmacol. Ther. 2001; 69: 114-121.
  • 19. Axelrod D., Bielory L.: Fexofenadine hydrochloride in the treatment of allergic disease: a review. J. Asthma Allergy 2008; 1: 19-29.
  • 20. Nettis E., Calogiuri G.F., Di Leo E. i wsp.: Once daily levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria. J. Asthma Allergy 2008; 2: 17-23.
  • 21. Labrecque M., Ghezzo H., LArcheveque J. i wsp.: Duration of effect of loratadine and terfenadine administered once a day for week on cutaneous and inhaled reactivity to histamine. Chest 1993; 103: 777-781.
  • 22. Almind M., Dirksen A., Nielsen N.H., Svendsen U.G.: Duration of the inhibitory activity on histamine-induced skin weals of sedative and non-sedative antihistamines. Allergy 1988; 43: 593-596.
  • 23. Bousquet J., Chanal I., Skassa-Brociek W i wsp.: Lack of subsensitivity to loratadine during long-term dosing during 12 weeks. J. Allergy Clin. Immunol. 1990; 86: 248-253.
  • 24. Kay G.G., Harris A.G.: Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Clin. Exp. Allergy 1999; 29 supl. 3: 147-150.
  • 25. Merlos M., Giral M., Balsa D. i wsp.: Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J. Pharmacol. Exp. Ther. 1997; 280: 114-121.
  • 26. Mullol J., Bousquet J., Bachert C. i wsp.: Rupatadine in allergic rhinitis and chronic urticaria. Allergy 2008; 63 supl. 87: 5-28.
  • 27. Keam S.J., Plosker G.L.: Rupatadine: a review of its use in the management of allergic disorders. Drugs 2007; 67: 457-474.
  • 28. Gimenez-Arnau A., Izquierdo I., Maurer M.: The use of a responder analysis to identify clinically meaningful differences in chronic urticaria patients following placebo controlled treatment with rupatadine 10 and 20 mg. J. Eur. Acad. Dermatol. Venereol. 2009; 23: 1088-1091.
  • 29. Grob J., Auquier P., Dreyfus I. i wsp.:. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy 2009; 64: 605-612.
  • 30. Weller K., Ardelean E., Scholz E. i wsp.: Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm. Venereol. 2012; doi: 10.2340/00015555-1434.
  • 31. Ciprandi G., Passalacqua G., Mincarini M. i wsp.: Continuous versus on demand treatment with cetirizine for allergic rhinitis. Ann. Allergy Asthma Immunol. 1997: 79: 507-511.
  • 32. Canonica G.W, Fumagalli F., Guerra L. i wsp.: Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study. Curr. Med. Res. Opin. 2008; 24: 2829-2839.
  • 33. Ciprandi G., Tosca M., Passalacqua G. i wsp.: Longterm cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Ann. Allergy Asthma Immunol. 2001; 87: 222-226.
  • 34. Ortonne J., Grob J., Auquier P. i wsp.: Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled, multicenter trial. Am. J. Clin. Dermatol. 2007; 8: 37-42.
  • 35. Grob J.J., Lachapelle J.M.: Non-sedating antihistamines in the treatment of chronic idiopathic urticaria using patient-reported outcomes. Curr. Med. Res. Opin. 2008; 24: 2423-2428.
  • 36. Bachert C., Maurer M.: Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin. Drug Investig. 2010; 30: 109-122.
  • 37. DuBuske L.: Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am. J. Clin. Dermatol. 2007; 8: 271-283.
  • 38. Augustin M., Ehrle S.: Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. J. Eur. Acad. Dermatol. Venereol. 2009; 23: 292-299.
  • 39. Potter P.C., Kapp A., Maurer M. i wsp.: Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy 2009; 64: 596-604.
  • 40. Singh-Franco D., Ghin H.L., Robles G.I. i wsp.: Levocetirizine for the treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children. Clin. Ther. 2009; 31: 1664-1687.
  • 41. Diepgen TL.: Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr. Allergy Immunol. 2002; 13: 278-286.
  • 42. Darsow U., Lubbe J., Tadeb A. i wsp.: Position paper on diagnosis and treatment of atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. 2005; 19: 286-295.
  • 43. Town G.I., Holgate S.T.: Comparison of the effect of loratadine on the airway and skin responses to histamine, metacholine and allergen in subjects with asthma. J. Allergy Clin. Immunol. 1990; 86: 886-893.
  • 44. Marmouz F., Giralt J., Izquierdo I.: Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trial. J. Asthma Allergy 2011; 4: 27-35.
  • 45. Bachert C., Kuna P., Sanquer F. i wsp.: Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009; 64: 158-165.
  • 46. Kuna P., Bachert C., Nowacki Z. i wsp.: Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin. Exp. Allergy 2009; 39: 1338-1347.
  • 47. Bachert C.: A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin. Ther. 2009; 31: 921-944.
  • 48. Katiyar S., Prakash S.: Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis. Prim. Care Respiro. J. 2009; 18: 57-68.
  • 49. del Cuvillo A., Sastre J., Montoro J. i wsp.: Allergic conjunctivitis and Hj antihistamines. J Invest. Allergol. Clin. Immunol. 2009; 19: 11-18.
  • 50. De Blic J., Wahn U., Billard E. i wsp.: Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. Pediatr. Allergy Immunol. 2005; 16: 267-275.
  • 51. Potter P.C., Paediatric Levocetirizine Study Group: Efficacy and safety of levocetirizine on symptoms and health-related quality of life of children with perennial allergic rhinitis: a double-blind, placebo-controlled randomized clinical trial. Ann. Allergy Asthma Immunol. 2005; 95: 175-180.
  • 52. Leynadier F., Mees K., Arendt C. i wsp.: Efficacy and safety of levocetirizine in seasonal allergic rhinitis. Acta Otorhinolaryngol. Belg. 2001; 55: 305-312.
  • 53. Bachert C., Bousquet J., Canonica G.W i wsp.: Levocetirizine improves quality of life and reduces costs in longterm management of persistent allergic rhinitis. J. Allergy Clin. Immunol. 2004; 114: 838-844.
  • 54. Pradalier A., Neukirch C., Dreyfus I. i wsp.: Desloratadine improves quality of life and symptom severity in patients with allergic rhinitis. Allergy 2007; 62: 1331-1334.
  • 55. Kim K., Sussman G., Hebert J. i wsp.: Desloratadine therapy for symptoms associated with perennial allergic rhinitis. Ann. Allergy Asthma Immunol. 2006; 96: 460-465.
  • 56. Rossi G.A., Tosca M.A., Passalacqua G. i wsp.: Evidence of desloratadine syrup efficacy and tolerability in children with pollen-induced allergic rhinitis. Allergy 2005: 60: 416-417.
  • 57. Martinez-Cócera C., De Molina M., Marti-Guadafio E. i wsp.: Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study. J. Investig. Allergol. Clin. Immunol. 2005; 15: 22-29.
  • 58. Saint-Martin F., Dumur J.P., Perez I. i wsp.: A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and Hj receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis. J. Investig. Allergol. Clin. Immunol. 2004; 14: 34-40.
  • 59. Okubo K., Gotoh M., Shimada K. i wsp.: Fexofenadine improves the quality of life and work productivity in Japanese patients with seasonal allergic rhinitis during the peak cedar pollinosis season. Int. Arch. Allergy Immunol. 2005; 136: 148-154.
  • 60. Ngamphaiboon J., Direkwattanachai C., Visitsunthorn N. i wsp.: The efficacy and safety of 30 mg fexofenadine HCl bid in pediatric patients with allergic rhinitis. Asian Pac. J. Allergy Immunol. 2005; 23: 169-174.
  • 61. Horak F., Zieglmayer P., Zieglmayer R. i wsp.: The effects of bilastine compared with cetirizine, fexofenadine, and placebo on allergen-induced nasal and ocular symptoms in patients exposed to aeroallergen in the Vienna Challenge Chamber. Inflamm. Res. 2010; 59: 391-398.
  • 62. Bartra J., Mullol J., Montoro J. i wsp.: Effect of bilastine upon the ocular symptoms of allergic rhinoconjunctivitis. J. Investig. Allergol. Clin. Immunol. 2011; 3: 24-33.
  • 63. Jauregui I., Bartra J., del Cuvillo A. i wsp.: Bilastine and quality of life. J. Investig. Allergol. Clin. Immunol. 2011; 21 supl. 3: 16-23.
  • 64. Devillier P., Roche N., Faisy C.: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin. Pharmacokinet. 2008; 47: 217-230.
  • 65. Hulhoven R., Rosillon D., Letiexhe M. i wsp.: Levoceti-rizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur. J. Clin. Pharmacol. 2007; 63: 1011-1017.
  • 66. Molimard M., Diquet B., Strolin-Benedetti M.: Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam. Clin. Pharmacol. 2004; 18: 399-411.
  • 67. Dhanya N.B., Thasleem Z., Rai R. i wsp.: Comparative efficacy of levocetirizine, desloratadine and fexofenadine by histamine wheal suppression test. Indian J. Dermatol. Venereol. Leprol. 2008; 74: 361-363.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-125245d8-a76d-48b5-99a9-5c5fc729036c
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.